Barclays initiated coverage of Kymera Therapeutics (KYMR) with an Overweight rating and $60 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics initiated with an Outperform at RBC Capital
- Kymera Therapeutics Announces New Chief Legal Officer
- Kymera Therapeutics appoints Adams as Chief Legal Officer, Corporate Secretary
- Kymera Therapeutics: Promising Clinical Developments and Strategic Positioning in STAT6 Landscape Justify Buy Rating
- Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress